Get started
Work

110RO Mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody–drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): Additional data from BEHOLD-1 study

Year: 2026
Type: article
Abstract: B7-H4 is highly expressed in OC and EC. Mo-Rez (GSK5733584), a novel ADC consisting of a humanized IgG1 monoclonal anti-B7-H4 antibody conjugated to a cyclopropyl-modified topoisomerase 1 inhibitor (drug–antibody ratio: 6), showed promising activity in global PROC and advanced/recurrent EC populations in BEHOLD-1 (NCT06431594). Here, we report additional data from the BEHOLD-1 study of Mo-Rez monotherapy, including B7-H4 expression and Mo-Rez activity by prior treatment.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2026.108157
Authors: I.L. Ray-Coquard, W.B. McKean, M.V. Dongen, J-Y. Lee, V. Moreno Garcia, V. Salutari, P.L. Bedard, V. Boni, R. Miller, J-W. Lee, M.C. Lim, J-S. Frenel, S.D. Shah, F.J. Gonzalez Carreras, A. Riccio, S. Zildjian, M.C. Kaisermann, J. Veneris, S. Lheureux, A. Oaknin
Institutions: Centre Léon Bérard, The Netherlands Cancer Institute, Yonsei University, Samsung Medical Center, Yonsei University Health System, Sungkyunkwan University, Hospital Universitario Fundación Jiménez Díaz, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, University of Toronto, Princess Margaret Cancer Centre, Hospital Universitario Quirónsalud Madrid, IDCQ Hospitales y Sanidad, S.L.U., St Bartholomew's Hospital, University College London, National Cancer Center, Institut de Cancérologie de l'Ouest, GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States), University Health Network, Hospital Universitario Puerta de Hierro Majadahonda
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7167087531
FWCI: 4.726
Cites:
Cited by: 1
Related to: